Canvax Releases New Inorganic Pyrophosphate

News
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, September 2022
Volume 17
Issue 9

Canvax’s new inorganic pyrophosphate is designed for in-vitro transcription reactions.

Canvax, a European supplier of enzymes, recombinant proteins, and similar products, announced the release of a new inorganic pyrophosphate on Aug. 25, 2022. The new enzyme, isolated from E. coli, is a DNA replication enhancer with ≥ 95% purity and has an enhanced capacity for increasing RNA yield in in-vitro transcription (IVT) reactions.

The enzyme has been stable under temperatures below 80º and is free of endonucleases, exonucleases, and RNAses. According to a company press release, this makes it ideal for use in RNA IVT reactions because it can reduce the inhibitory effects of protein-protein interactions. The company also stated in the release that it is suitable for messenger RNA-based vaccine manufacturing, RNA labeling, and enhancement of DNA replication.

“We're glad to contribute with this new launch, significantly to supporting mRNA vaccines manufacturing, and we're pleased that the research community has embraced our pyrophosphatase and our RNA enzymes portfolio,” said Jesus C. Morales, business development manager, Canvax, in the release.

Source: Canvax

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content